Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zerlasiran single-ascending-dose PK/PD and safety study in Japanese subjects with elevated lipoprotein(a)
jRCT2051240068Phase 1Completed
- Sponsor
- Silence Therapeutics
- Start
- May 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zerlasiran in lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Silence Therapeutics. Primary endpoint: Pharmacokinetic parameters of zerlasiran. Started May 2024; status: completed.
02
Drugs
zerlasiran
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on jRCT2051240068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240068.